No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year
No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year
复制标题
DOI：
10.1111/j.1365-2796.2009.02181.x
复制
发表时间：
2010-05-01
影响因子：
11.1
通讯作者：
Figenschau, Y.
中科院分区：
文献类型：
--
作者：
Jorde, R.;Sneve, M.;Figenschau, Y.
Jorde R、Sneve M、Torjesen P、Figenschau Y（特罗姆斯大学圈划分、特罗姆斯圈划分；北挪威医学诊所大学医院、特罗姆斯圈划分；北挪威大学医院、特罗姆斯圈划分；奥斯陆阿克大学医院；北挪威大学医院、特罗姆斯圈划分；以及特罗姆斯大学圈划分、特罗姆斯圈划分；挪威）。补充维生素 D-3 一年后，超重和肥胖受试者的心血管危险因素没有改善。实习医学杂志，2010； 267:462-472.背景和目的。横断面研究表明维生素 D 对葡萄糖耐量、血压和血脂很重要，但补充维生素 D 是否会改善心血管危险因素尚不清楚。设计和设置。该研究是一项为期 1 年、双盲安慰剂对照干预试验，于 2005 年 11 月至 2007 年 10 月在北挪威大学医院进行。受试者。总共 438 名超重者纳入 21-70 岁或肥胖受试者，330 名完成研究。 干预措施。受试者随机接受维生素 D（胆钙化醇、维生素 D-3）每周 40 000 IU（DD 组）、维生素 D 每周 20 000 IU（DP 组）或安慰剂（PP 组）。所有受试者每天服用 500 毫克钙。主要结果指标。测量空腹血脂和血压，并在研究开始和结束时进行口服葡萄糖耐量试验。结果。基线时，平均血清 25(OH)D 水平为 58 nmol L-1（所有受试者），DD 和 DP 组分别增加至 140 和 101 nmol L-1。三组之间在葡萄糖代谢或血脂测量值的变化方面没有发现显着差异。与安慰剂组相比，DP 组的收缩压有轻微但显着的升高。结论。我们的结果不支持维生素 D 对葡萄糖耐量、血压或血脂的积极作用。需要对血清 25(OH)D 水平低且伴有糖耐量受损、高血压或血脂异常的受试者进行进一步研究。
Jorde R, Sneve M, Torjesen P, Figenschau Y (University of Troms circle divide, Troms circle divide; Medical Clinic University Hospital of North Norway, Troms circle divide; University Hospital of North Norway, Troms circle divide; Aker University Hospital, Oslo; University Hospital of North Norway, Troms circle divide; and University of Troms circle divide, Troms circle divide; Norway). No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D-3 for 1 year. J Intern Med 2010; 267:462-472.Background and Aim.Cross-sectional studies indicate vitamin D to be of importance for glucose tolerance, blood pressure and serum lipids, but whether supplementation with vitamin D would improve cardio-vascular risk factors is not known.Design and Setting.The study was a 1 year, double blind placebo-controlled intervention trial performed at the University Hospital of North Norway from November 2005 to October 2007.Subjects.A total of 438 overweight or obese subjects, 21-70 years old, were included and 330 completed the study.Interventions.The subjects were randomized to vitamin D (cholecalciferol, vitamin D-3) 40 000 IU per week (DD group), vitamin D 20 000 IU per week (DP group), or placebo (PP group). All subjects were given 500 mg calcium daily.Main Outcome Measures.Fasting serum lipids and blood pressure were measured and an oral glucose tolerance test performed at start and end of the study.Results.At baseline the mean serum 25(OH)D levels were 58 nmol L-1 (all subjects) and increased to 140 and 101 nmol L-1 in the DD and DP groups, respectively. No significant differences were found between the three groups regarding change in measures of glucose metabolism or serum lipids. In the DP group, there was a slight but significant increase in systolic blood pressure compared with the placebo group.Conclusions.Our results do not support a positive effect of vitamin D on glucose tolerance, blood pressure or serum lipids. Further studies in subjects with low serum 25(OH)D levels combined with impaired glucose tolerance, hypertension or dyslipidaemia are needed.